SPHK2 and psoriasis: Considering the complicating off-target effects of ABC294640 [15,24], we re-investigated the effects of topical SK2 inhibition in psoriasis-like skin disease using the newly developed selective SK2 inhibitor, HWG-35D [17] and using the same dosage used for ABC294640 to enable a direct comparison [17,21].